<i>TP53</i> suppression promotes erythropoiesis in del(5q) MDS, suggesting a targeted therapeutic strategy in lenalidomide-resistant patients
Gisela Cáceres(Moffitt Cancer Center), Alan F. List(TE Laboratories (Ireland))
Cited by 53
Related Papers
Donor leukocyte infusions in 140 patients with relapsed malignancy after allogeneic bone marrow transplantation.
|Journal of Clinical Oncology|1997|1.3k
Efficacy of Lenalidomide in Myelodysplastic Syndromes
|New England Journal of Medicine|2005|874
A macaque clonal hematopoiesis model demonstrates expansion of TET2-disrupted clones and utility for testing interventions
|Blood|2022|38
Oxidized Mitochondrial DNA Engages TLR9 to Activate the NLRP3 Inflammasome in Myelodysplastic Syndromes
|International Journal of Molecular Sciences|2023|38
Erythropoietin Receptor Signaling Is Membrane Raft Dependent
|PLoS ONE|2012|32